Earnings summaries and quarterly performance for Tempest Therapeutics.
Research analysts covering Tempest Therapeutics.
Recent press releases and 8-K filings for TPST.
Tempest Therapeutics Announces Positive Interim REDEEM-1 Trial Results for TPST-2003
TPST
New Projects/Investments
- Tempest Therapeutics announced positive interim results from its ongoing REDEEM-1 Phase 1/2a trial for TPST-2003, a CD19/BCMA dual-targeting CAR-T therapy for relapsed/refractory multiple myeloma (rrMM).
- As of January 31, 2026, all six efficacy evaluable patients in the REDEEM-1 trial achieved a 100% complete response (CR) rate, with a favorable safety profile showing no Grade > 3 cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS).
- A prior Phase 1/2 investigator-initiated trial (IIT) also demonstrated a median progression-free survival (PFS) of 23.1 months and a 100% overall response rate (ORR) among 19 evaluable patients.
- Based on these results, Tempest plans to submit a U.S. IND application and initiate a U.S. registrational study for TPST-2003 in 2026.
Feb 25, 2026, 1:09 PM
Tempest Therapeutics, Inc. Updates on Oncology Pipeline Progress and Regulatory Milestones
TPST
New Projects/Investments
- Tempest Therapeutics, Inc. (TPST) provided an updated corporate presentation in February 2026, highlighting a diversified oncology pipeline with partner-funded development.
- The company's lead asset, Amezalpat (TPST-1120), a PPARα antagonist for 1L HCC, has received FDA Orphan Drug Designation in December 2024 and Fast Track Designation in January 2025, with FDA, EMA, and NMPA agreement on a pivotal Phase 3 study. Phase 2 data as of February 14, 2024, showed a six-month improvement in median overall survival (21 months vs. 15 months) over the control arm.
- TPST-2003, a CD19/BCMA Dual CAR-T for relapsed/refractory multiple myeloma (rrMM), completed a Phase 1/2a clinical trial, demonstrating a 100% objective response rate (ORR) and 88.9% stringent complete response/complete response (sCR/CR) in hematological response (n=18). The company plans to submit a China BLA in 2027.
- TPST-1495, a first-in-class dual EP2/4 antagonist for Familial Adenomatous Polyposis (FAP), is expected to have its First Patient In (FPI) in a Phase 2 study in 1H26, with the study funded by the NCI.
Feb 11, 2026, 12:14 PM
Tempest Therapeutics Outlines Post-Transaction Strategy for CAR-T and Oncology Assets
TPST
New Projects/Investments
M&A
Guidance Update
- Tempest Therapeutics has outlined a capital-efficient post-transaction strategy to advance its newly acquired CAR-T and oncology assets, prioritizing partner-funded and externally supported programs to generate clinical data before deploying significant internal capital.
- The company plans to advance TPST-2003, a dual-targeting CD19/BCMA CAR-T therapy, with a registrational Phase 2b in China expected by the end of 2026, funded by a strategic partner.
- Tempest will expand its portfolio with TPST-4003, an in vivo CAR-T program, and initiate a Phase 2 study of TPST-1495 in Q1 2026, which is expected to be externally funded by the National Cancer Institute.
- Additionally, Tempest aims to position amezalpat for pivotal development through business development and progress other next-generation dual-targeting CAR-T programs like TPST-3003, TPST-2206, and TPST-3206.
Feb 11, 2026, 11:59 AM
Tempest Therapeutics Completes Asset Acquisition, Announces Leadership Changes, and Issues Warrants
TPST
M&A
CEO Change
Board Change
- Tempest Therapeutics, Inc. completed the acquisition of CAR T-cell therapy assets from Erigen LLC and Factor Bioscience Inc. on February 3, 2026, issuing 8,268,495 shares of common stock as consideration.
- Following the asset acquisition, Erigen LLC became the majority owner, holding approximately 61.3% of the outstanding common stock, with a total of 13,481,070 shares outstanding immediately after the share issuance.
- The company distributed 6,784,989 warrants on February 3, 2026, each allowing the purchase of one common stock share at an exercise price of $18.48, with an expiration date of February 3, 2031.
- Dr. Matthew Angel was appointed President and Chief Executive Officer and a Class I director on February 3, 2026, succeeding Stephen Brady, who resigned from these roles; additionally, Geoff Nichol resigned from the Board.
Feb 6, 2026, 9:12 PM
Tempest Therapeutics Closes Acquisition of CAR-T Assets and Appoints New CEO
TPST
M&A
CEO Change
New Projects/Investments
- Tempest Therapeutics has closed an all-stock transaction to acquire dual-targeting CAR-T programs and secure financing support from Factor Bioscience Inc..
- This transaction extends the company's operational runway to mid-2027.
- Matt Angel, Ph.D., has joined Tempest as President and Chief Executive Officer.
- The acquired assets include TPST-2003, a clinical-stage dual-targeting CD-19/BCMA CAR-T, with a Biologics License Application (BLA) filing in China planned for 2027.
Feb 4, 2026, 9:47 PM
Tempest Therapeutics Announces Registered Direct Offering and Private Placement
TPST
- Tempest Therapeutics, Inc. announced a registered direct offering of 1,172,414 shares of common stock (or equivalents) at $3.625 per share, and a concurrent private placement of short-term unregistered warrants to purchase up to 1,172,414 shares of common stock at an exercise price of $3.50 per share.
- The offering, expected to close on or about November 25, 2025, is with a single healthcare-focused institutional investor.
- The company anticipates receiving approximately $4.25 million in gross proceeds from the offering, with potential additional gross proceeds of approximately $4.1 million if the warrants are fully exercised, for a total potential of up to $8.35 million.
- The net proceeds from this offering are intended primarily for working capital and general corporate purposes.
Nov 26, 2025, 1:55 PM
Tempest Therapeutics Announces Q3 2025 Financial Results
TPST
Earnings
New Projects/Investments
Demand Weakening
- Tempest Therapeutics reported a net loss of $3.5 million, or $0.79 per share, for the third quarter ended September 30, 2025, compared to a net loss of $10.6 million, or $5.32 per share, for the same period in 2024.
- The company concluded Q3 2025 with $7.5 million in cash and cash equivalents, a decrease from $30.3 million on December 31, 2024, primarily due to cash used in operating activities.
- Research and development expenses significantly decreased to $0.6 million in Q3 2025 from $7.6 million in Q3 2024, mainly due to re-prioritizing efforts towards exploring strategic alternatives.
- Tempest is continuing its strategic alternatives process to maximize stockholder value and anticipates the start of the TPST-1495 Phase 2 trial in collaboration with the NCI.
Nov 5, 2025, 2:04 PM
Tempest Therapeutics Reports Third Quarter 2025 Financial Results
TPST
Earnings
M&A
New Projects/Investments
- Tempest Therapeutics reported a net loss of $3.5 million and net loss per share of $0.79 for the third quarter ended September 30, 2025, compared to $10.6 million and $5.32 respectively for the same period in 2024.
- The company ended the quarter with $7.5 million in cash and cash equivalents, a decrease from $30.3 million on December 31, 2024, primarily due to cash used in operating activities.
- Research and development expenses significantly decreased to $0.6 million for Q3 2025 from $7.6 million for Q3 2024, mainly due to re-prioritizing efforts towards exploring strategic alternatives.
- Tempest is continuing its strategic alternatives process to maximize value for stockholders and anticipates the start of the TPST-1495 Phase 2 clinical trial.
Nov 5, 2025, 1:30 PM
Fintool News
In-depth analysis and coverage of Tempest Therapeutics.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more